Ipca Laboratories (IPCALAB) Q1 24/25 earnings summary

Executive summary

• Domestic formulation business grew 12% in Q1 FY25, outpacing the Indian pharma market's 9% growth and increasing market share to 2.17% from 2.06% year-over-year.

• Standalone net total income rose 3% to Rs. 1,581.25 crores; consolidated net total income surged 30% to Rs. 2,113.24 crores for Q1 FY25.

• Standalone net profit increased 23% to Rs. 204.13 crores; consolidated net profit grew 18% to Rs. 192.24 crores year-over-year.

• Export formulation business declined 1-4% due to logistics and supply chain challenges, particularly in Australia and New Zealand.

• API business declined 2% year-over-year, with price erosion now limited to 2-3%.

Financial highlights

• Standalone EBITDA margin for Q1 FY25 was 22.25%, exceeding the annual guideline of 21%.

• Consolidated EBITDA margin reached 18.52%, above the 18% guidance.

• Standalone income from operations grew 5% year-over-year, below the 10.5-11% guidance due to export headwinds.

• Standalone EPS (after exceptional items) was Rs. 8.05, up 23%; consolidated EPS was Rs. 7.58, up 18%.

• Standalone finance cost dropped 37% to Rs. 19.42 crores; consolidated finance cost down 23% to Rs. 24.05 crores.

Outlook and guidance

• Full-year revenue growth expected at 9%, revised down from 10.5-11% due to Q1 export shortfall.

• Profitability for FY25 projected to exceed previous guidance, with consolidated EBITDA margin likely to surpass 20.5-21%.

• Export growth expected to recover in coming quarters as logistics improve, but Q1 shortfall unlikely to be fully bridged.

• US market launches planned: 5-6 products in FY25, 6-7 more in FY26, targeting 12-13 products over two years.

• Q1 FY25 figures are not strictly comparable to Q1 FY24 due to Unichem consolidation from Q2 FY24.